# LatInamerican Vaccine Effectiveness Against Hospitalizations Due to Circulating COVID-19 VoC RWE Study

> **NCT05282017** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 792 (actual)

## Conditions studied

- COVID-19, SARS-CoV-2

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05282017
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-01
- **Primary completion:** 2023-04-19
- **Final completion:** 2023-04-19
- **Target enrollment:** 792 (ACTUAL)
- **Last updated:** 2024-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05282017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05282017, "LatInamerican Vaccine Effectiveness Against Hospitalizations Due to Circulating COVID-19 VoC RWE Study". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05282017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*